Forecasting and Orders Sample Clauses

Forecasting and Orders. (a) Xxxxxx acknowledges and agrees that all forecasts and Firm Orders shall be subject to the maximum monthly Whole Lot quantities set forth in Exhibit C attached hereto.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Forecasting and Orders. On or before sixty (60) days prior to each calendar quarter, NuVasive shall provide to Osiris a binding order (“Order”) for the quantity and size of Product to be delivered by Osiris to NuVasive in the following calendar quarter. Each Order shall be in writing, and shall specify the quantity of units of Product by size, the brand name of each unit of Product ordered, the requested Delivery date(s), the destination shipping address(es), and the Product Fees therefor. Osiris shall be required to supply to NuVasive all such quantities of Product as NuVasive orders pursuant to such Orders in accordance with the Product unit sizes and brand names specified in such Orders and shall use its commercially reasonable best efforts to conform to the requested Delivery date(s) set forth in such Orders, provided in each case such Orders do not exceed the Minimum Performance Levels during the applicable periods set forth in Section 3.3 below. Osiris shall deliver the Product to NuVasive pursuant to the Orders, subject to available Product being released for transplantation; provided, that the Parties understand and agree the final Delivery dates for Orders may vary from the requested dates based upon Donor Tissue procurement.
Sample 1Sample 2Sample 3
Forecasting and Orders. 13.1 Within [***] following the submission of a MA Application through the EMA centralized procedure and then on a monthly basis throughout the applicable Product Schedule Term,
Sample 1Sample 2
Forecasting and Orders. SAVIENT shall forecast and order the Activated PEG as follows:
Sample 1Sample 2
Forecasting and Orders. CREALTA shall forecast and order the Activated PEG as follows: [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
Sample 1
Forecasting and Orders i. Within thirty (30) days following completion of Product Testing and Product Approvals under the terms of the Product Development Schedule as provided for in the Product Development Agreement, Womens3D shall provide TechniScan with a rolling forecast of its estimated purchases of Products that Womens3D intends to or will (as applicable) order from TechniScan over the following twelve (12) months. The last nine (9) months of any forecast shall be prepared in good faith but shall constitute non-binding estimates and not legally binding commitments of Womens3D, but the first three (3) months of each forecast shall constitute a binding commitment of Womens3D to purchase, in accordance herewith, the amount of Products set forth in such forecast for such period and a binding obligation by TechniScan to supply Products timely and in accordance with this Agreement and the forecast. Womens3D’s order(s) hereunder shall cumulatively be for no less than $1,500,000 to be paid to TechniScan (which amount shall be fully credited towards satisfaction of the Initial Development Fee) within twelve (12) months following FDA approval (the “Minimum Initial Order”).
Sample 1
Forecasting and Orders. CREALTA shall forecast and order the Activated PEG as follows: ***Confidential Treatment Requested
Sample 1
AutoNDA by SimpleDocs

Related to Forecasting and Orders

  • Forecasts and Orders 4.1 Customer shall provide IBM’s customer account representative with a Product demand forecast, which shall cover a minimum of twelve (12) months broken out by Product and month. By the fifth (5th) day of every month during the term of this Attachment, Customer will provide IBM’s customer account representative with an updated Product demand forecast covering a rolling twelve (12) month period (not to extend beyond the term of this Attachment), which will be reviewed for approval by IBM within ten (10) days of receipt by IBM. Forecasts shall constitute good faith estimates of Customer’s anticipated requirements for Products but shall not contractually obligate IBM to supply, nor contractually obligate Customer to purchase, the quantities of Product set forth in such forecasts.

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Marketing Plans Contractor and the Exchange recognize that Enrollees and other health care consumers benefit from efforts relating to outreach activities designed to increase heath awareness and encourage enrollment. The parties shall share marketing plans on an annual basis and with respect to periodic updates of material changes. The marketing plans of the Exchange and Contractor shall include proposed and actual marketing approaches, messaging and channels and provide samples of any planned marketing materials and related collateral as well as planned, and when completed, expenses for the marketing budget. The Contractor shall include this information for both the Exchange and the outside individual market. The Exchange shall treat all marketing information provided under this Section as confidential information consistent with Section 1.4.1. The obligation of the Exchange to maintain confidentiality of this information shall survive termination or expiration of this Agreement.

  • Quality Assurance The parties endorse the underlying principles of the Company’s Quality Management System, which seeks to ensure that its services are provided in a manner which best conforms to the requirements of the contract with its customer. This requires the Company to establish and maintain, implement, train and continuously improve its procedures and processes, and the employees to follow the procedures, document their compliance and participate in the improvement process. In particular, this will require employees to regularly and reliably fill out documentation and checklists to signify that work has been carried out in accordance with the customer’s specific requirements. Where necessary, training will be provided in these activities.

  • SEC Reporting and Compliance (a) Parent filed a registration statement on Form SB-2 under the Securities Act which became effective on February 1, 2002 and was not withdrawn, and a registration statement on Form 10-SB under the Exchange Act, which became effective on October 15, 2001. Since October 15, 2001 and except as set forth on Schedule 3.8, Parent has timely filed with the Commission all registration statements, proxy statements, information statements and reports required to be filed pursuant to the Exchange Act. Parent has not filed with the Commission a certificate on Form 15 pursuant to Rule 12h-3 of the Exchange Act.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!